Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lauren Sciences LLC maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action, which represents the entirety of the company's active engagement with the patent office. This matter is assigned to 1 distinct examiner, GREENE, IVAN A, who serves as the busiest examiner for the portfolio. GREENE, IVAN A currently oversees the pending office action, representing the total active volume for the company.
The administrative footprint of the portfolio is limited to a distinct art unit. This level of concentration means that the company's immediate patent outcomes are tied to the specific examination practices of the assigned individual and the technical group within the Biotechnology & Pharmaceuticals field. For a practitioner, this indicates a lack of diversification across different examiners or art units, making the specific preferences and history of GREENE, IVAN A the primary factor in current prosecution success. The focused nature of this portfolio requires a strategy tailored to the specific precedents and tendencies of the assigned examiner and the administrative standards of the art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17351373 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GREENE, IVAN A | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17351373 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GREENE, IVAN A | 1619 | §103 | Final Rejection | — | Pending | Jun 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLauren Sciences LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ivan A Greene has the most, with 1 of Lauren Sciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
